Compare Enovix Corporation (ENVX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs ResMed Inc. — how do they compare? Enovix Corporation trades at $4.6 (market cap $1.11B), while ResMed Inc. trades at $201.1 (market cap $28.80B). The key difference: ResMed Inc. is far larger — about 25.9× Enovix Corporation's market cap, and ResMed Inc. pays a 1.21% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ENVX | RMD | |
|---|---|---|
Market Cap | $1.11B | $28.80B |
Sector | Technology | Health |
52-Week High | $15.93 | $293.73 |
52-Week Low | $4.84 | $182.82 |
Enterprise Value | $1.13B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX is trading at $4.59, down 9.29% in the last session, with a bearish technical signal. The company shows consistent quarterly earnings beats but remains deeply unprofitable with a -499.64% net income margin. Recent positive developments include the appointment of a former Apple operations leader as COO and progress in commercial battery production for smart eyewear and smartphone markets.
Despite analyst optimism (75% buy ratings, $12.75 consensus target), ENVX faces significant execution risks as it scales production. The stock offers speculative growth potential in advanced battery technology but requires substantial revenue acceleration to justify current valuations amid persistent cash burn and negative profitability.
ResMed (RMD) trades at $201.44, up 4.37% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 27.44% net margins and consistent revenue growth from $3.6B in 2022 to $5.15B in 2025. Recent strategic moves include divesting MatrixCare for $490M to sharpen focus on core sleep and respiratory care markets.
RMD presents a compelling growth story with analyst consensus pointing to 28% upside potential to $245.88. However, technical weakness and competitive pressures in the medical device space warrant caution. The company's strong cash flow generation and dividend payments provide shareholder value, but investors should monitor execution risks from the business portfolio restructuring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
